TScan Therapeutics (NASDAQ:TCRX) Issues Earnings Results, Misses Expectations By $0.02 EPS

TScan Therapeutics (NASDAQ:TCRX) announced its quarterly earnings data on Wednesday. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02), Zacks reports. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%.

TScan Therapeutics Price Performance

Shares of TCRX traded down $0.06 on Wednesday, reaching $1.96. The stock had a trading volume of 61,141 shares, compared to its average volume of 308,761. TScan Therapeutics has a twelve month low of $1.82 and a twelve month high of $9.69. The firm has a market capitalization of $104.77 million, a PE ratio of -1.84 and a beta of 0.87. The firm has a 50-day moving average of $2.47 and a 200 day moving average of $4.07. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

Wall Street Analysts Forecast Growth

TCRX has been the topic of a number of analyst reports. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research note on Wednesday, December 11th. Wedbush reissued an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Monday, December 23rd. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.